This is a preview of subscription content, log in via an institution to check access.
Notes
In its first assessment (January 2012), IQWiG was unable to determine any added benefit because Boehringer Ingelheim had chosen sitagliptin as comparator therapy instead of a sulfonylurea as specified by the Federal Joint Committee.
Reference
Stafford N. New drug for type 2 diabetes is no better than older, cheaper treatments, says institute. BMJ : 19 Dec 2012. Available from: URL: http://dx.doi.org/10.1136/bmj.e8593
Rights and permissions
About this article
Cite this article
No proof of added benefit with linagliptin, says IQWiG. PharmacoEconomics & Outcomes News 669, 10 (2013). https://doi.org/10.1007/s40274-013-0066-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0066-6